After Myriad, what makes a gene patent claim 'markedly different' from nature?
MetadataShow full item record
Aboy, M., Liddicoat, J., Liddell, K., Jordan, M., & Crespo, C. (2017). After Myriad, what makes a gene patent claim 'markedly different' from nature?. Nature biotechnology, 35 (9), 820-825. https://doi.org/10.1038/nbt.3953
Examining the types of claim amendments that have transformed isolated gene claims from patent-ineligible into eligible subject matter provides clarity into the threshold of eligibility for gene-related patents.
External DOI: https://doi.org/10.1038/nbt.3953
This record's URL: https://www.repository.cam.ac.uk/handle/1810/298135
All rights reserved